Cytocidal effect and DNA damage of nedaplatin: a mathematical model and analysis of experimental data

Citation
Y. Miyagi et al., Cytocidal effect and DNA damage of nedaplatin: a mathematical model and analysis of experimental data, CANC CHEMOT, 47(3), 2001, pp. 229-235
Citations number
31
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN journal
03445704 → ACNP
Volume
47
Issue
3
Year of publication
2001
Pages
229 - 235
Database
ISI
SICI code
0344-5704(200103)47:3<229:CEADDO>2.0.ZU;2-W
Abstract
Purpose: Cell cycle non-specific anticancer agents such as cis-diamminedich loroplatinum(II) are believed to depend linearly on the value of the area u nder the drug concentration time curve, which is supported by a mathematica l model. However, the quantitative non-linear phenomena of both the cytocid al effect and DNA crosslink formation by cisdiammine(glycolato)platinum (ne daplatin) have been shown in vitro. Therefore, we developed a new mathemati cal model to explain these phenomena. Methods: We assumed that nedaplatin e nters intracellular fluid from medium through simple diffusion to form DNA crosslinks that kill cells. We developed a mathematical model to represent this assumption using differential equations that we then solved using an o riginal computer program. The calculated results were compared with the exp erimental data. Results: The drug's simple diffusion rate constant, the DNA crosslink formation rate constant, and the crosslink-dependent cell death rate constant in the model were 1.8 x 10(-14) (1 h(-1)), 1.6 x 10(8) (1 mol (-1/2) h(-1)), 5.45 x 10(1) (mol(-1)), respectively. The model fits the exp erimental results statistically. The model also demonstrated theoretical pr oof that continuous exposure at a low dose was superior to the short exposu re at a high dose seen in published experimental data. Conclusions: We deve loped a mathematical model to describe the non-linear pharmacodynamic effec t of nedaplatin in vitro. This model may provide a novel drug infusion proc edure for cancer patients.